Physician profile
Edwin Laurence Jacobs
NPI 1366462939
$3,824.31
in general payments reported to CMS, 2019-2025
34 companies · $34.99 in 2025
The $34.99 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,979 · 2020: $16.47 · 2021: $48.74 · 2022: $209 · 2023: $271 · 2024: $265 · 2025: $34.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $357.12 | 2019-2023 | |
| Amgen INC. | $314.19 | 2019-2023 | Lumakras |
| Novartis Pharmaceuticals Corporation | $303.82 | 2019-2024 | |
| Genentech USA, INC. | $238.24 | 2019 | |
| Seagen INC. | $235.24 | 2019-2023 | Adcetris, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $219.37 | 2019 | |
| Eisai INC. | $197.35 | 2019-2022 | |
| Celgene Corporation | $156.70 | 2019-2023 | |
| Genzyme Corporation | $147.43 | 2019 | |
| Merck Sharp & Dohme LLC | $146.62 | 2019-2024 | Keytruda |
| Janssen Biotech, INC. | $125.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.77 | 2019-2024 | Opdualag |
| Incyte Corporation | $122.15 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $115.01 | 2019-2024 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $111.20 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.35 | 2019-2022 | |
| Puma Biotechnology, INC. | $92.38 | 2019 | |
| Gilead Sciences, INC. | $86.49 | 2019-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $85.74 | 2019-2024 | |
| Lilly USA, LLC | $68.19 | 2019-2023 | Verzenio, Jaypirca |
| Clovis Oncology, INC. | $61.11 | 2019 | |
| Glaxosmithkline, LLC. | $57.08 | 2022-2024 | Zejula, Jemperli |
| Astellas Pharma US INC | $56.18 | 2019 | |
| Jazz Pharmaceuticals INC. | $42.63 | 2019 | |
| Abbvie INC. | $40.78 | 2019 | |
| Adc Therapeutics America, INC. | $36.41 | 2021 | |
| Janssen Pharmaceuticals, INC | $34.71 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $28.49 | 2023 | Bard Urinary Drainage Bag |
| Daiichi Sankyo INC. | $26.07 | 2024 | Enhertu |
| Eusa Pharma (US) LLC | $25.88 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.01 | 2019 | |
| Rigel Pharmaceuticals, INC. | $16.64 | 2022 | |
| Shionogi INC | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.